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Abstract: This review focuses on the biological action of the compounds from the group of substituted
1,3,4-thiadiazines on stress response and myocardial infarction. The aim of this review is to propose
the possible mechanisms of action of 1,3,4-thiadiazines and offer prospectives in the development of
new derivatives as therapeutic agents. It is known, that compounds that have biological effects similar
to those used as antidepressants can down-regulate the secretion of proinflammatory cytokines,
up-regulate the release of anti-inflammatory ones and affect cell recruitment, which allows them to be
considered immunomodulators as well. The results of pharmacological evaluation, in silico studies,
and in vivo experiments of several compounds from the group of substituted 1,3,4-thiadiazines with
antidepressant properties are presented. It is proposed that the cardioprotective effects of substituted
1,3,4-thiadiazines might be explained by the peculiarities of their multi-target action: the ability of the
compounds to interact with various types of receptors and transporters of dopaminergic, serotonergic
and acetylcholinergic systems and to block the kinase signal pathway PI3K-AKT. The described
effects of substituted 1,3,4-thiadiazines suggest that it is necessary to search for a new agents for
limiting the peripheral inflammatory/ischemic damage through the entral mechanisms of stress
reaction and modifying pro-inflammatory cytokine signaling pathways in the brain.
Keywords: 1,3,4-thiadiazines; immunomodulators; myocardial infarction; PI3K-AKT signaling
pathway; stress response
1. Introduction
It has been well recognized that the course of many diseases, the pathogenesis of which involves
changes in the immune system, can be modified by the administration of biologicals or chemicals that
activate or suppress key pathways in the immune system. However, in the medical literature, one finds
multiple and conflicting definitions for the terms immunosuppression and immunomodulation
depending on the author, publication, or agency defining these terms [1]. According to Lebish
(1987), immunomodulators are “those intrinsic or extrinsic substances which regulate or alter the
scope, type, duration or competency of the immune response” [2]. The term “regulation”, in this or
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similar definitions, always includes the ability of substances to upregulate or downregulate specific
aspects of the host response [3]. The properties of immunomodulators were limited only to the
restoration of immune system functions in some later definitions. According to this point of view,
immunomodulators are medicines that restore the functions of the immune system in therapeutic
doses (effective immune defense), by lowering the increased and increasing the lowered immunity [4].
Moreover, some researchers even categorize agents based on the most clinically relevant data, which are
the documented occurrences of immune-mediated, clinically relevant complications that are compiled
from the actual human data [1–5]. According to them, immunomodulators refer to those agents that
modulate the immune response to control inflammatory disease activity without being associated with
a statistically significant increased risk of clinically manifested immune-mediated complications [1].
The direction of an immunomodulator’s action (and the previous state of the immune system), with that
definition, is not mentioned at all. Finally, according to the U.S. Food and Drug Administration
(FDA) guidelines, immunomodulators are the non-vaccine and non-allergenic products intended
to treat disease by inhibiting or down-regulating a pre-existing, pathological immune response [5].
Thus, the later definition postulated not only the direction of action (inhibiting or down-regulating)
and the state of immune response (the exaggerated), but also the chemical nature of compounds,
separating them from vaccines, antibodies, enzymes and cytokines. The FDA’s definition is mostly
clear, although it is not without shortcomings, as it excludes some possible mechanisms of action by
these agents (described by Lebish, 1987), such as increasing the ability of the host to tolerate damage
by cytotoxic modality, augmenting and/or restoring effector mechanisms or mediators of host defense,
or replacing the damaged effector or mediator mechanisms [2]. Moreover, the possible links between
the immune response and stress reaction, which often accompany the disturbances of the former,
also slip out of sight.
Selye, in 1936, defined stress physiologically as the state in which the sympathoadrenomedullary
system and the limbic-hypothalamic-pituitary-adrenal axis (HPA) are coactivated [6]. Recently,
the understanding of the interactions between the HPA axis and inflammatory reactions mediated by
the immune system has expanded greatly, with many studies showing that stress can affect various
parts of the cellular immune response [7]. Experimental and clinical studies have shown that both
artificial and natural stressors alter the activity of cellular affecters of the immune system (lymphocytes
and macrophages), and these changes depend on the type of immune response, the physical and
psychological characteristics of the stressor, the duration of its action, and also on the initial state of the
immune system [8]. With that, according to the traditional interpretation of stress-immune interactions,
the immunosuppressive nature of the stress response is an example of the harmful, pathological effects
of stress on the body [9].
However, more recently this interpretation has changed, and some stress hormone effects are
now interpreted as an adaptive redistribution of immune resources [10–12]. According to Adamo,
(2017) the stress response and the immune system should be viewed not as independent entities, but as
different parts of a larger defensive system [10]. This defensive system is itself embedded within
the web of the animal’s total physiological network. Some network pathways are shared between
the stress and immune responses [10]. This sharing can lead to both conflict and cross-tolerance.
Under some conditions, network pathways are also borrowed between the two responses, and some
pathways become reconfigured [10]. Stress hormones, for example, help reconfigure immune resources
to enhance protection against wound infections during fight-or-flight behavior [11]. Even the
chronic effects of stress hormones are context-dependent; immunosuppression is not necessarily
the outcome [13]: many animals have evolved under a chronic threat of predation, which led to the
increased stress levels, but those elevated levels do not appear to reduce the disease resistance [10].
That is why the neuroendocrine and immune systems have common signal mediators and
receptors, while the brain has an immunoregulatory role, and the immune system has a sensory
function [14]. This finds confirmation in the results of in vivo and in vitro experiments, where the
neurotransmitters such as norepinephrine, serotonin, dopamine, and acetylcholine; neuropeptides
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such as enkephalins, substance P, vasoactive intestinal peptide, corticotrophin-releasing factor,
and neuropeptide Y; neurohormones such as growth hormone, adrenocorticotropin hormone,
and prolactin; and adrenal hormones such as corticosteroids and epinephrine, affect the immune
functions, while the receptors for these molecules are present on surface of immune cells [7].
Among the neurotransmitters mentioned, the three cytokines—tumor necrosis factor, interleukin-1,
and interleukin-6 secreted from activated immune cells are the primary agents, which can in turn
change the function of the hypothalamic–pituitary–adrenal (HPA) axis. These three proinflammatory
cytokines activate the HPA axis independently as well as in combination. Moreover, inflammation
might also activate the HPA axis indirectly. This could occur through the stimulation of the central
noradrenergic stress system by cytokines and other mediators that act first on stress-system neurons
outside the blood–brain barrier (the area postrema) or on neurons inside the barrier, through
the endothelial–glial–neuronal cascade mentioned above [10]. Additionally, inflammatory sites
contain nociceptive, visceral, and somatosensory afferent neurons, which stimulate the noradrenergic
and corticotropin-releasing hormone stress systems through an ascending spinal or cerebral nerve
route [10,15]. All of these observations suggest that, since any immunomodulatory agent will affect the
stress response, the substances that affect the latter might, in turn, have an immunomodulatory effect.
2. Materials and Methods
2.1. The Possibility of Influencing the Functions of the Immune System via the Central Mechanisms of the
Stress Response
This view finds confirmation. According to the literature, antidepressant drugs, which affect
depression and stress, were frequently shown to impact the dysregulated immune response in
depressed patients [16], mostly by improving the serum cytokine profile during therapy [17–19],
which might result from their influence on cytokine release [19–23] or through their action on
lymphocytes and macrophages [24,25]. Moreover, due to the impact of antidepressants on serotonin
turnover, it can be speculated that antidepressants might alter the immune response at the early stage
of cell recruitment to the site of inflammation, which, among others, depends on platelet-derived
serotonin [26]. Among the recent studies, the work of K. Nazimek et al. (2016), revealed the direct
impact of various antidepressant drugs on macrophages and have shown that administration of
some of them (fluoxetine, venlafaxine, and moclobemide) resulted in suppression of humoral and
cell-mediated immunity with a reduction of the release of macrophage proinflammatory mediators
and the expression of antigen-presentation markers [27]. Thus, compounds that have biological effects
similar to those used as antidepressants can down-regulate the secretion of proinflammatory cytokines,
up-regulate the release of anti-inflammatory ones [26] and affect cell recruitment, which allows them
to be considered immunomodulators as well.
Many experimental and clinical studies were conducted in accordance with the evidence that
stress affects the immune system and even delays wound healing [28]. Malinin et al. (2004),
having summarized the available data on the history of serotonin metabolism and mechanism of
action of ketanserin, suggested that the topical use of selective serotonin reuptake inhibitors (SSRIs)
might represent a promising avenue for future strategies affecting wound repair in high-risk patients,
especially those with diabetes mellitus, venous insufficiency, obesity, and other vascular disorders [29].
Subsequently, it was shown that fluoxetine significantly improved healing of cutaneous wounds in
stressed and, to a lesser extent, in non-stressed animals and paroxetine administration enhanced
wound healing by increasing the number of fibroblasts and causing better epithelialization over time
in healthy but not in diabetic rats [30]. However, the negative impact of SSRIs is also described in the
literature, as fluoxetine was shown to exert a direct, inhibitory effect on osteoblast differentiation and
mineralization in disparate models of bone repair [31]. Thus, the clinical implications of these findings
need further investigation.
Some studies also examined the effects of midazolam, a commonly used benzodiazepine,
upon burn wound healing. Babcock et al. (2012) treated mice with midazolam (1 mg/kg) daily
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after a burn injury and observed a decrease in IL-1β, TNF-α, IL-6, IL-10, and TGF-β levels compared
to saline-treated mice [32]. Another study by this group, using the same treatment with midazolam,
investigated whether psychological stress (such as predator exposure) could alter survival following
Pseudomonas aeruginosa infection [33]. The results showed that midazolam had a protective effect in
mice. Together, these studies suggest that benzodiazepines can modulate the immune system and a
host of inflammatory mediators, leading to a detrimental effect on healing and tissue regeneration.
The beneficial effects from pre-surgical interventions, which lowered the intensity of stress in some
studies were also revealed. These beneficial effects included decreased anxiety and stress reductions
when hospitalized, fewer post-operative complications, better treatment compliance, less pain and
reduced use of analgesics, and alterations in various physiological indices [28,34]. Given the substantial
consequences of stress, even small reductions in anxiety could have substantial clinical consequences,
both directly and indirectly [28]. More broadly, researchers have used several diverse strategies to
modulate immune function via influence on stress-reaction, including relaxation, hypnosis, exercise,
classical conditioning, self-disclosure and cognitive behavioral interventions [28]. These interventions
generally have produced positive endocrine and immune changes [35–37]. Although it is not yet clear
to what extent these positive immunological changes translate into any concrete improvements in
relevant aspects of health, such as alterations in the incidence, severity or duration of infectious and/or
malignant disease, the preliminary evidence seems to be promising [28].
2.2. The Compounds from the Group of Substituted 1,3,4-Thiadiazines
Among the promising compounds that act like immunomodulators are the substituted
1,3,4-thiadiazines (Table 1). A variety of biological activities has been reported for many thiadiazine
derivatives, such as antimicrobial [38–41], antihelmintic [42], anti-inflammatory [43,44], analgesic [45],
anticancer [45,46], tuberculostatic [47] and anti-aggregant [48–50] activities (Table 1).
Table 1. Chemical structures of substituted 1,3,4-thiadiazines, mentioned in the text.
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Some of the compounds are able to inhibit the non-enzymatic glycosylation of proteins in
experiments in vitro [51] and to cause hypothermia in experiments in vivo [52]. Several substituted
1,3,4-thiadiazines were provided as anaesthetic, cardiovascular and hypometabolic agents [53].
With that, even the superficial analysis of published works indexed in databases Scopus, WoS and
Pubmed shows that most researchers focused on the antibacterial/antifungal properties of this class of
compounds (Figure 1).
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Figure 1. Estimated types of activity of 1,3,4-thiadiazines. Legend: the graph presents data on the types
of biological activity described in the literature for 1,3,4-thiadiazines. The data may be incomplete,
since they were obtained on the basis of a search query from December 2016 (1,3,4-thiadiazines AND
[1,3,4]thiadiazines) in Scopus/Web of Science/Pubmed. 272 p pers were found on these compounds,
of which the presence/absence of biological effects was described in 132. The patents were not included
in the search.
2.3. The Action of the Compounds from the Group of Substituted 1,3,4-Thiadiazines on Myocardial Ischemia
and Myocardial Infarction
In the CheMBL 24.1 database 3768 records of the compounds, the structure of which includes
the 1.3.4-thiadiazine cycle, were found. However, there were no substances among them that have
been investigated for the presence of any cardiotropic activity (including the myocardial ischemia and
myocardial infarction). In the same database (CheMBL 24.1), 366 records, describing the experimental
testing of the new substances on the model of myocardial infarction were found. Among them,
only two compounds contained the substructure fragment with sulfur and nitrogen in the cycle.
The chemical structures and the properties of those compounds are presented in Tables 2 and 3.
Table 2. Chemical structure of compounds CHEMBL2104951 and CHEMBL2440857.
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Table 3. Biological action of the compounds CHEMBL2104951 and CHEMBL2440857.
ChEMBL ID,
Name, Code Assay Description Activity ID Activity
CHEMBL2104951
Aladorian
ARM036 S36
Induction of cardiac function improvement in myocardial
infarction-induced acute heart failure mouse model at plasma
concentration 200 nM after 7 days post myocardial infarction.
16878971 Active
Induction of cardiac function improvement in myocardial
infarction-induced acute heart failure mouse model subjected to
permanent ligation of left anterior descending coronary artery
assessed as increase in fractional shortening at plasma
concentration of 100 to 200 nM after 2 weeks post-myocardial
infarction by echocardiography.
16878972 Active
Induction of cardiac function improvement in myocardial
infarction-induced acute heart failure mouse model subjected to
permanent ligation of left anterior descending coronary artery
assessed as increase in cardiac contractility at plasma
concentration 200 nM after 7 days post-myocardial infarction.
16878973 Active
CHEMBL2440857
JTV-519
Reduction in PKA-phosphorylation of RyR2 in myocardial
infarction-induced heart failure mouse model at 0.5 mg/kg/h
after 28 days post-myocardial infarction.
16878976 Active
Improvement in soleus muscle fatigability in myocardial
infarction-induced heart failure mouse model at 0.5 mg/kg/day
relative to control.
16878983 Active
Improvement in soleus muscle fatigability in myocardial
infarction-induced heart failure calstabin2-deficient knockout
mouse at 0.5 mg/kg/day relative to control.
16878984 Active
Normalization of RYR1 in myocardial infarction-induced heart
failure mouse soleus muscle assessed as increase in average
channel open dwell time.
16878985 t = 1.5 ms
Normalization of RYR1 in myocardial infarction-induced heart
failure mouse soleus muscle assessed as decrease in average
channel close dwell time.
16878986 t = 1567 ms
Induction of calstabin-1 binding to RYR1 in myocardial
infarction-induced heart failure wild type mouse soleus muscle at
0.5 mg/kg/day dosed via implantable osmotic minipumps.
16878996 Active
Inhibition of of PKA-induced RyR1 phosphorylation in
myocardial infarction-induced heart failure mouse soleus muscle
at 0.5 mg/kg/day dosed via implantable osmotic minipumps.
16878997 Active
Induction of calstabin-1 binding to RYR1 in myocardial
infarction-induced heart failure calsiabin2−/− mouse soleus
muscle at 0.5 mg/kg/day dosed via implantable osmotic
minipumps.
16878998 Active
In the PubMed and ScienceDirect search engines, no publications were published on the activity
of 1,3,4-thiadiazines in myocardial infarction, other than those referenced in this review [48–54] (search
query “thiadiazine myocardial infarction”).
Thus, the described latitude of biological activity spectrums of substituted thiadiazines, as well
as the previous experimental data [53,54], serves as the basis for conducting the series of studies of
the compound’s immunomodulatory properties in silico and in vivo. The aim of in silico studies is to
outline the spectrum of biological activity of the compounds and to identify the potential mechanisms
of action.
3. Experiment
3.1. Pharmacological Evaluation
Based on the previous data, the pharmacological evaluation in vivo and in vitro for
anti-psychotic/antidepressant activity of the series of substituted 1,3,4-thiadiazines was conducted.
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According to the conducted pharmacological study in vivo and in vitro, the leading compound L-17
(2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide), possessed the combination of adrenergic
properties, as well as certain characteristics of choline and serotonin blockers and acted like the atypical
antipsychotic agent Eglonyl (sulpiride) [54].
3.2. In Silico Studies
In silico determination of the most promising targeted activities for the leader compound
(2-morpholino-5-phenyl-6H-1,3,4-thiadiazine hydrobromide) and the prediction of the most promising
target activity spectrum for compound L-17, was performed in several stages: first, via computer
program BBB Predictor 0.90 [55], the potential blood–brain barrier (BBB) penetration was evaluated
followed by the use of two prediction algorithms (AdaBust, SVM) and four methods for descriptor
representation of the chemical structures (MACCS, OpenbabelFP2, Molprint 2D, PubChem); the 8 pairs
of scoring functions were calculated: BBB+, the ability of the compound to accumulate in the CNS,
BBB−, and the alternative score. The result was a 10% truncated mean BBB +/BBB− ratio, which was
1.78 for the L-17 compound. The obtained value reflected the high ability of the L-17 compound to
penetrate the BBB and, consequently, to exhibit the psychotropic properties.
Second, via the program PASS 10.4 Professional Extended [56], the prediction for the
presence/absence of 480 systemic types of pharmacological activity was performed. Promising
activities were those for which the calculated probability of having activity Pa was ≥0.1 and the
likelihood ratio between Pa/Pi was ≥1.0, where Pi was the calculated probability of lack of activity.
Taking into account the high ability of compound L-17 to penetrate the BBB and the results of
its pharmacological evaluation [52], the following activities were identified for further targeted
analysis: general anesthetic (Pa = 0.413, Pa/Pi = 304.33), anesthetic (Pa = 0.464, Pa/Pi = 35.69),
cognition disorders treatment (Pa = 0.489, Pa/Pi = 27.17), anti-inflammatory (Pa = 0.625, Pa/Pi = 23.15),
phobic disorders treatment (Pa = 0.703, Pa/Pi = 9.37), psychotropic (Pa = 0.258, P /Pi = 1.74),
immunostimulant (Pa = 0.191, Pa/Pi = 1.39), antinociceptive (Pa = 0.271, Pa/Pi = 1.32), cardiovascular
analeptic (Pa = 0.170, Pa/Pi = 1.21), antidepressant (Pa = 0.162, Pa/Pi = 1.14).
The prediction of the presence/absence of the linked target activities was performed during the
third stage of the in silico study, for the aforementioned target systemic types of pharmacological
activity, using the PharmaExpert 10.1 program [57]. According to joint predictive evaluations in PASS,
PharmaExpert and experimental data [52], the most likely targeted activities corresponding to the
systemic pharmacological effects of compound L-17 were found: 5-hydroxytryptamine 3 receptor
antagonist (Pa = 0.139, Pa/Pi = 1.17), 5-hydroxytryptamine release inhibitor (Pa = 0.225, Pa/Pi = 1.01),
acetylcholine agonist (Pa = 0.154, Pa/Pi = 7.00), benzodiazepine agonist (Pa = 0.141, Pa/Pi = 5.64),
benzodiazepine omega receptor agonist (Pa = 0.385, Pa/Pi = 2.89), calpain inhibitor (Pa = 0.375,
Pa/Pi = 19.74), cholinergic (Pa = 0.153, Pa/Pi = 3.26), complement factor D inhibitor (Pa = 0.430,
Pa/Pi = 4.06), GABA B receptor agonist (Pa = 0.163, Pa/Pi = 1.46), GABA receptor agonist (Pa = 0.257,
Pa/Pi = 6.27), glutamate release inhibitor (Pa = 0.113, Pa/Pi = 1.53), Janus tyrosine kinase inhibitor
(Pa = 0.193, Pa/Pi = 6.43), Neurotransmitter uptake inhibitor (Pa = 0.470, Pa/Pi = 6.35). A separate
analysis in the PASS program revealed that the L-17 compound practically did not act on the
glutamatergic system (for glutamate, AMPA, NMDA and kainate receptors).
While the L-17 compound manifests itself as an atypical mild antipsychotic, antidepressant
and adrenoblocker, with serotonergic, cholinergic (blocking), adrenergic (blockade of α1-adrenergic
receptors), dopaminergic, GABA-ergic, and glutamatergic actions [54], for the subsequent analysis of
its multitarget mechanism of action the following 15 target proteins were chosen. The list of proteins
included the serotonin receptor type 3A (5-HT3A), the serotonin transporter (SERT), the muscarinic
cholinergic receptor type 1 (CHRM1), the dopamine receptor type 1 (DRD1), the dopamine receptor
type 2 (DRD2), the dopamine transporter (DAT), the α1-adrenoreceptor (ADRA1A), the noradrenaline
transporter (NET), the α1-subunit of GABA-A receptor (GABRA1), the β2-subunit of GABA-A
receptor (GABRB2), the γ2-subunit of GABA-A receptor (GABRG2),the GABA transporter of type 1
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(GAT1), Janus tyrosine kinase type 3 (JAK3), the calpain 1 (CAPN1), and the complementary factor D
(adipsin) CFD.
Furthermore, for a comparative evaluation of the L-17 compound’s affinity to the selected
biotargets, the docking of the compound to the specific binding sites of these proteins was performed.
Experimental X-ray 3D models were obtained from Protein Data Bank in Europe [58] for 5 targets
and for each target protein the longest model, with the maximum resolution including an inhibitor,
was chosen among all available models to allow the unambiguous determination of the binding site’s
position. The models with PDB codes 5I6X [59], 5CXV [60], 3LXL [61], 1ZCM [62], 1DIC [63] for SERT,
CHRM1, JAK3, CAPN1, CFD, respectively, were found. Information on the binding site for adipsin
CFD was obtained from [64]. The experimental 3-D models were not available in the Protein Data Bank
in Europe for 10 targets, and therefore a search for the best theoretical 3-D models from the Database of
Comparative Protein Structure Models [65] was conducted. Among the available models, the longest,
with the highest statistical significance, were selected, while the data on binding sites was found
in available literature. The models with the following Internal ID ModBase were found (references
are given to works with data about binding sites): e056050ca26ea7251f01816dc9bccde8 [66];
28b6261001683ffd97d78ffc6fd4448a [67]; 091bc097c64a5a1726ec1a99b9228fc4 [68];
664e40366933e7b160379446201fbf4e [69]; 0be8c685ba7d1551a3f2c7252e9c72c7 [70];
b99b37c984483657d38cd8fe9c006809 [71]; b3709eea5375f1242ba57ac4b578cded,
8e2807a55eac507927d600810aaf5386, b5b3593bf4fc198659b14bdfb9ee4ba4 [72];
6ef1240e3cc222adef0ad22bb83881ae [73]; for 5-HT3A, DRD1, DRD2, DAT, ADRA1A, NET,
GABRA1, GABRB2, GABRG2, GAT1, respectively.
The 3-D model of the L-17 compound was constructed using the molecular mechanics methods in
the MarvinSketch program 15.6.15 [74], followed by optimization with the semi-empirical quantum
chemical method PM7 in the MOPAC2016 program [75]. The docking was performed using
AutoDockVina 1.1.2 [76], five times per target, including calculating the minimum binding energy.
The values of the docking energy ∆E of the L-17 compound in the binding sites were −6.6,
−8.1, −8.3, −8.1, −7.9, −7.8, −7.4, −8.0, −6.1, −6.3, −7.4, −8.0, −6.5, −6.0 kcal/mol for 5-HT3A,
SERT, CHRM1, DRD1, DRD2, DAT, ADRA1, NET, GABA and benzodiazepine sites of GABA-A
receptor, GAT1, JAK3, CAPN1 and CFD, respectively. According to the molecular docking data,
the L-17 compound had a pronounced multitarget effect. The properties of the holinoblocker were
most pronounced in the L-17 compound, which was characterized by the best docking energy in the
M1-cholinoreceptor. Dopaminergic properties were also expressed, which were formed from activity
against DRD1 and DRD2 and DAT inhibition. The next, most important factor for the compound
L-17 was α1-adrenergic blocking activity due to a moderate effect on ADRA1 and a pronounced effect
on NET. The moderate serotonin-blocking effect of L-17 was due, above all, to a sufficiently high
affinity for SERT; the direct antagonism to 5-HT3A receptors was negligible. The possible presence of a
moderate GABAergic effect due to the GAT1 transporter blocking properties was revealed; while the
direct interaction with the GABA-binding and benzodiazepine sites of the GABA-A receptor was not
significant. There is a high inhibitory activity of the compound L-17 against JAK3 kinase. The inhibition
of the other two target proteins, involved in the processes of inflammation and apoptosis (CALPN1
and CFD), was insignificant.
Based on the above results, for a working hypothesis it was suggested that one of the main
mechanisms of the anti-inflammatory action of the compound L-17 was the inhibition of JAK3;
thus, in the framework of this hypothesis, the in silico of the targeted mechanism of anti-inflammatory
action of L-17 was conducted.
In Silico Study of the Targeted Mechanism of Anti-Inflammatory Action of Compound L-17
According to the PASS/PharmaExpert predictions and the docking results, the L-17 compound
should exhibit Janus tyrosine kinase (JAK) inhibitory activity. It is known that JAKs participate in the
signal transduction from the cytokine receptors along the JAK-STAT [77] signaling pathway through
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the PI3K-AKT signaling pathway [78] and play a key role in the formation of inflammatory processes
and the enhancement of apoptosis. Inhibition of JAK3 by pharmacological agents on a myocardial
ischemia/reperfusion (I/R) model in mice significantly decreased plasma creatine kinase and lactate
dehydrogenase activities, reduced infarct size, reversed I/R-induced functional deterioration of the
myocardium, and reduced myocardial apoptosis [79]. Conversely, ischemia/reperfusion, hypoxia,
aging, hyperglycemia, inflammation and the oxidative stress accompanying all these processes led
to the formation of advanced glycation end-products (AGEs) [80]. AGEs interact with specific AGE
receptors (RAGE), which also activate the PI3K-AKT signaling pathway, which in turn leads to the
activation of NF-κB [81] and, ultimately, to the increase in inflammation and apoptosis and, possibly,
the occurrence of cancer.
To determine the most probable multitarget mechanism of anti-inflammatory action of the
L-17 compound, according to the protocol described above, the docking of this compound was
performed to specific binding sites of PIK3CA (alpha catalytic subunit of phosphatidylinositide
3-kinase), AKT1 (protein kinase B alpha), RAGE and NF-κB1 (nuclear factor kappa-B p50 subunit).
Regarding these four target proteins, optimum experimental X-ray 3D models from Protein Data
Bank in Europe [58] with PDB codes2RD0 [82], 5KCV [83], 3O3U [84] and 1SVC [85] for PIK3CA,
AKT1, RAGE and NF-kB1, respectively, were found. According to the results obtained, the values
of the docking energy ∆E of the L-17 compound in binding sites were estimated as −8.0, −7.3, −8.4,
−5.5, −5.8 kcal/mol for JAK3, PIK3CA, AKT1, RAGE and NF- κB1, respectively. Obviously, L-17 did
not block RAGE and NF- κB1, but exhibited high affinity for the three kinases JAK3, PIK3CA and
AKT1. It can be argued that in this regard, with a fairly high probability, the anti-inflammatory
effect of substance L-17: (1) was not related to the signal transduction from RAGE to NF-κB;
(2) was due to trinary blocking of kinase signal pathway PI3K-AKT; (3) included the significant
immunotropic component.
Concerning the most affine to L-17 compound AKT1 kinase with ∆E = −8.4 kcal/mol, an analysis
of the molecular binding mechanism was performed using the program Ligand Scout 4.2 Advanced [86]
(Figure 2). It is seen that the high binding energy of the L-17 molecule to the AKT1 site was due
to 5 hydrogen bonds and two hydrophobic interactions, one of which is very extensive and affects
4 amino acid residues.
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3.3. In Vivo Studies
3.3.1. Action of Substituted 1,3,4-Thiadiazines on the Course of Stress Reaction
Considering that 1,3,4-thiadiazines revealed effects similar to those of atypical antipsychotics
in experiments in vivo, its effects on the course of stress reaction were investigated. The model of
immobilization stress used in those experiments was described by Kvetnansky: rats were immobilized
fixing their backs to an operation table for 6 h a day for 2 days [87]. Histological, morphological,
as well as biochemical studies and immunoassays were performed on the first and second day of the
experiment. According to the results obtained, on the background of 3,4-thiadiazines administration
there was a significant change in the cellular composition of the blood on the second day: an increased
concentration of a mixture of monocytes, eosinophils, basophils, and immature cells in the blood was
detected. The glucose level in animals treated with the compounds was significantly lower than in
control animals (8.0 ± 0.6 versus. 9.8 ± 0.2) [88].
Since the main target organs under stress are the thymus (stress causes the involution of the
thymus lymphatic system) and adrenal glands (hypertrophy of the adrenal cortex), the targeted
histological examination of those organs was conducted. According to the results, on the background
of L-17 compound administration, the medulla of the thymic lobules retained numerous lymphoid
elements, which suggested strengthening of lymphopoiesis [88]. With that, in control animals, thinning
of the cortical layer, obliteration of the boundaries between the cortical and medulla layers in the
lobules as well as denudation of the stroma of the organ were observed after stress [88]. Moreover,
similar changes were described in the in the adrenal glands of control animals: dilated sanguineous
blood vessels in the medullary; signs of thromb formation were visible in some; and diffuse extension
of vessels at the cortex/medulla boundary [88]. In the pancreas, the consistent increase in the surface
area of pancreatic islets and the density of distribution of insulin-producing cells was also observed
after L-17 compound administration. This confirms that the L-17 compound influences the stress
response because the insulin production is curtailed during the resistance phase and at the start of the
depletion phase of stress [89].
Taken together with the results of pharmacological evaluation and behavioral studies,
the aforementioned results enabled us to suggest that substituted thiadiazines lower the reaction
to stress. With that, the described action of compound L-17 does not contradict the previous data of
the pharmacological study and is similar to the action of atypical neuroleptic sulpiride: according to
Benelli et al. (2000) treatment with low doses of l-sulpiride lowers the reaction to stress and prevents
the development of gastric lesions induced by chronic exposure to uncontrollable stress [90].
Interestingly, according to the literature, drugs acting on the dopaminergic system (including
sulpiride), revealed the immunomodulatory effects not only on models of stress damage, but also
in such severe diseases as myocardial infarction (MI). According to Tagliavini et al. (1992) specific
dopamine antagonists (I-sulpiride) was able to limit ischemia- and reperfusion-induced myocardial
damage [91]. Later clinical works showed the beneficial effects of sulpiride on the patients with MI
which manifested itself in the decrease in the number of anginal attacks and their severity [92].
Thus, based on the data of the above studies and the similarity of the sulpiride and the L-17
compound according to the analysis of the affinity spectra, the authors were able to assume that
the administration of L-17 compound will reduce the stress response and improve the course of
stress-related coronary heart diseases and MI [88]. Moreover, several compounds from the group
of substituted 1,3,4-thiadiazines (including the L-17 compound) exerted the immunomodulatory
properties on experimental models of severe stress and MI.
3.3.2. Action of Substituted 1,3,4-Thiadiazines on the Course of Myocardial Infarction
It should be noted that in cardiovascular diseases, stress damage most often plays one of the main
roles in the development of pathological disturbances [93,94], and the heart being the main target for
the stress reaction is described in the literature [89,95].
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The confirmation of the presence of stress-induced myocardial infarction in the current studies
were the levels of aspartate aminotransferase (AST) after immobilization stress, which were
significantly higher in the stressed animals in comparison with the control ones and were similar to
AST levels in the animals with myocardial infarction (25.6 ± 1.5 U/L after immobilization stress and
24.9 ± 2.0 U/L in 24 h after myocardial infarction) [88]. Modelling of MI in rats was performed in
accordance with the authors’ modification of standard ligation model. Histological, biochemical and
immunobiochemical studies were performed at days 1, 5, 7 and 14 of the experiment [96,97].
According to the results obtained using L-17 compound administration, significant changes in
the histological picture of the heart were observed on the first day of experimental MI. Animals of
the control group (with MI induced) had the transmural MI typical for this species [98], which was
characterized by the cardiomyocyte’s death in all layers of the heart. The developed MI was located
subepicardially, based on L-17 compound administration. The histological picture of the infarction zone
on the background of L-17 compound administration was also different: on the first day of experimental
MI, the diffuse infiltration of segmented leucocytes which persisted until the 7th day was observed
in control animals, while only the lesion zone without a pronounced perifocal exudative reaction
was observed after the L-17 compound administration. The decrease in the number of neutrophils
observed could cause a decrease in the depth of lesion and the intensity of the inflammatory reaction
in experimental MI. The early entry of mononuclear cells (macrophages and lymphocytes) into the
damaged tissues, which are necessary for effective resolution of inflammation [99], including the
absorption of apoptotic and necrotic cells and the activation of fibroblasts which contributes to the
formation of granulation tissue and neoangiogenesis [100], was also detected.
Administration of L-17 compound also led to the earlier and more active reparative process
in the affected area. Thus, in control animals, the signs of formation of granulation tissue were
revealed only on the seventh day and only in the structures adjacent to the necrotic zone, while on
the background of L-17 compound administration, the granulation tissue had appeared in the zone of
subacute inflammation by the fifth day of the experiment and had replaced the infarction zone almost
completely by the seventh day, with endothelial capillary cells involved in the formation of sinusoidal
capillaries, appearing on the fifth day [96,97]. The observed histological picture indicated that the
administration of L-17 compound in MI, decreasing the entry of neutrophils into the inflammation zone
and increasing the supply of macrophages, revealed the immunomodulatory effect, manifested itself
in the change of the exudative-destructive type of inflammation to the proliferative-cellular [96,97].
The results of the biochemical study revealed that the activity of AST, alanine transaminase (ALT)
and creatine kinase-MB (CPK MB) in the animals on the background of L-17 compound administration
was significantly lower than in the animals of the control group (Figure 3). Moreover, on the fifth
day of the experiment, the activity of ALT and the activity of CPK MB did not differ significantly in
comparison with intact animals. Concurrently, in animals of the control group with experimental MI,
the rise of CPK MB activity on the seventh day exceeding the first day’s activity was detected [96].
Considering that the activity of serum CPK in patients with MI is considered as one of the sensitive
diagnostic methods of diagnosing myocardial infarction, the repeated rise of CPK activity in the control
group might be considered as the sign of MI recurrence [101].
Additional to the routine evaluation of the activity of enzymes in the blood plasma, their activity
in the homogenate of the myocardium was defined [102]. The comparison of lactate dehydrogenase 1,2
(LDH 1,2) and CPK activity in blood and in myocardial homogenate revealed the principal differences
between the animals of the experimental (with the L-17 compound administration) and control groups.
Thus, on the first day in both groups the decrease in LDH 1,2 activity in the homogenate coincided with
its increase in blood, which is typical for the onset of MI, while on the seventh day of the experiment
the animals of the experimental group displayed low activity of LDH 1,2 in myocardial homogenate,
corresponding to the decrease in activity in the blood, which eliminated the possibility of re-infarction.
The animals of the control group showed the repeated increase in LDH 1,2 in the blood on the 7th
day of the experiment corresponded to the low enzyme activity in the myocardial homogenate, which
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confirmed the presence of recurrent MI [71]. Similar changes were observed on the seventh day of the
experiment for CPK activity; the activity of CPK in blood corresponded to normal values in myocardial
homogenate in the animals of the experimental group, while in the control group the increased
activity of CPK MB in the blood, even in comparison with the first days of the experiment, was not
accompanied by a change in the activity of CPK MB in the homogenate [102]. Thus, the evaluation
of enzyme levels in myocardial tissue confirms previously reported data that the administration of a
thiadiazine compound prevents recurrence and decreases the size of experimental MI.
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Since the clinical significance of hypercytokinemia in MI is not in doubt, and both the magnitude
of the developing MI and the likelihood of complications depend on its severity [103], the levels of
pro-inflammatory and anti-inflammatory cytokines (TNF, IL-1, IL-6 and IL-10) were determined [95].
According to the results obtained, at 24 h after MI the levels of interleukins in control group animals
exceeded the norm for IL-1 by 8 times, for TNF by 7.8 times, for IL-6 by 2.5 times and for IL-10 in 4,3
times. Concurrently, in the animals of the experimental group with the compound L-17 administration,
the increase in interleukin levels was significantly lower: IL-1 was increased 1.8 times, TNF-4.7-fold,
IL-10–2.2-fold, and IL-6 level below the norm 2 times [97].
Considering the possibility of the development of systemic inflammation in MI and of objectifying
the effects of the revealed hypercytokinemia on the severity of the inflammatory reaction, the values
of the reactivity coefficient (CR) and the reactivity level (UR) by Gusev et al. (2008) were
calculated [104,105]. The calculations revealed that in the animals of the control group the reactivity
coefficient reached 11, which corresponded to fourth level reactivity—the “forecast zone” of critical
complications, at which the development of a systemic inflammation process might begin when
TNF-α, IL-1β and IL-6 are produced not only by cardiomyocytes, but also by endothelial cells [105,106].
Moreover, on the background of L-17 compound administration, the reactivity coefficient reached
nine, which corresponded to the third level of reactivity, typical for the hyperreactive form of classical
inflammation, and did not differ from the indices of the sham-operated animals. Thus, one of the
main effects of L-17 compound administration in animals with MI was the prevention of its recurrence,
confirmed by biochemical and histological data. This effect and the absence of subendocardial
damage, can be explained, first, by the changes in the microcirculation state caused by a decrease
in the levels of circulating cytokines, which trigger the intravascular coagulation processes [107,108].
Additionally, high levels of circulating cytokines might cause the dose-dependent vasoconstriction of
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A2–A4 arterioles [109], stimulating local neutrophilia and platelet aggregation [110] and activating
procoagulant and prothrombotic processes on endothelial cells [111] which, in turn, cause the
disturbances in the microcirculation state.
The decrease in the size of necrosis in experimental MI on the background of L-17 compound
administration, indirectly assessed by AST activity, suggested the possibility of the compound’s
influence on the cardiomyocytes apoptosis activity. Subsequently, the study showed that on the
background of L-17 compound administration, the intensity of apoptosis initiated via extrinsic pathway
(CD 95) was significantly higher than in control animals throughout the experiment, while the intensity
of apoptosis initiated via intrinsic pathway (P 53) was higher on the seventh day of the experimental
MI [112]. The fact that the significantly higher apoptosis activity rates on the background of L-17
compound administration corresponded to significantly lower AST activity, in comparison with the
control animals, indicated the reduction in the intensity of cell death by necrosis at the same time.
4. Discussion
The Proposed Mechanisms of Action of Substituted 1,3,4-Thiadiazines
The revealed cardioprotective effects of substituted thiadiazines might be explained by the
peculiarities of their multi-target action: the ability of the compounds to interact with various types of
receptors and transporters of dopaminergic, serotonergic and acetylcholinergic systems and to block
the kinase signal pathway PI3K-AKT (Figure 4). Since the activity of these systems makes a significant
contribution to the pathogenesis of MI, the complex effect on them leads to significant changes during
the pathological process and determines the occurrence of the described cardioprotective effects.
Thus, the multi-target action of thiadiazine compounds affected both the manifestations of the stress
reaction and the course of developed MI.
One can propose that, on the basis of thiadiazines administration, there occurred an increase in
the stress-resistivity of neurons (action through D2 receptors) [113] and a decrease in the levels of
stress cytokinemia (from critical levels, observed after MI) [114,115], which was mediated through
SERT [17,113] and central M1 receptors [113] and was accompanied by the decrease in the stress
hormonal response due to the blockade of M1 receptors [116], a stress-mediated decline in insulin
production in the pancreas and the occurrence of stress hyperglycemia due to the action on the
dopamine system [90,117]. Reduction of the peripheral organs (thymus, adrenal glands) reaction under
stress was due to action of the compounds through NET, M1 and D2 receptors [118,119].
Substituted thiadiazines in the myocardium, acting through the D-receptors, intensified the
apoptosis processes and increased macrophage infiltration [120], thereby having reduced the release of
pro-inflammatory cytokines by the latter and lymphocytes. The blockade of muscarinic receptors led
to the suppression of the intensity of the local inflammatory process due to inhibition of chemotaxis
and the migration of leukocytes [121], which led to the reduction in leukocyte infiltration and tissue
damage [122].
Synergistic effects of serotonergic [123,124], adrenergic [125] and cholinergic [126] system
blockades on the processes of platelet activation and aggregation prevented the development of
microcirculatory disorders which contribute significantly to the recurrence of MI. Moreover, the L-17
compound’s ability to block kinase signal pathway PI3K-AKT, predicted in in silico studies, also
might be responsible for the appearance of the described effects on experimental MI since, according
to the literature, the inhibition of JAK3 significantly decreases the plasma creatine kinase and
lactate dehydrogenase activities and reduces the infarct size [79]. Consequently, in the animals with
experimental MI, using 1,3,4-subsituted thiadiazine administration, the described pattern was noted,
characterized by a less pronounced cytokinemia and stress increase in glucose, a less pronounced
involution of target organs, in the myocardium with smaller MI dimensions [59], and a decrease in the
frequency of its recurrence accompanied with the change of the inflammation type to a productive one.
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Figure 4. The proposed immunopathophysiological mechanisms of stress-limiting effects of
1,3,4-thiadiazine compounds in myocardial infarction (based on the compound L-17 properties).
Legend: blue—the main mechanisms of action of the substituted 1,3,4-thadiazines on the course
of stress reaction are highlighted; red—mechanisms acting on the tissue damage; yellow—action
of the compounds on the serotonin-mediated disorders of microcirculation. Systemic effects of
1,3,4-thadiazines included: (1) the increase in neuronal stress-resistance mediated through D2 receptors;
(2) the increase in synaptic availability of 5-HT, mediated via SERT and M1 receptors; (3) the reduction
in the levels of stress cytokinemia, mediated via NET, M1 and D2 receptors; (4) the reduction of
stress hormonal response and sensitivity of pituitary-adrenal system mediated through blockade of
M1 receptors; (5) the reduction of stress-mediated decrease in insulin production in the pancreas
and prevention of stress hyperglycemia due to action on dopamine receptors; (6) the decrease in of
blood glucose levels, which, on the background of M-cholinoreceptor blockade, led to the decrease
inoxidative stress in tissues. Local effects of substituted 1,3,4-thadiazines included: (i) the reduction
of oxidative stress levels and the suppression of the intensity of the local inflammatory process by
inhibiting chemotaxis and migration of leukocytes, which was mediated through the blockade of
muscarinic receptors and the kinase signal pathway PI3K-AKT; (7) the increased apoptosis, increased
macrophage infiltration, decreased macrophage release of proinflammatory cytokines via blockade
of D-receptors; (8) the decreased platelet activation and aggregation preventing the development of
microcirculatory disorders and, as a consequence, secondary damage to the myocardial tissues (9–10)
through a synergistic blockade of the serotonergic and adrenergic systems.
Molecules 2018, 23, 1611 15 of 22
5. Conclusions
While the stress response and the immune systems are different parts of the larger defensive
system [10], some might discover some immunomodulatory effects, and vice versa. This concept was
confirmed by the series of studies [19–29] and found confirmation in the current studies [96,97,112].
Thus, it was found that several chemical compounds of the group of substituted thiadiazines possessed
the attributes of atypical antipsychotics, having a significant effect on the behavior of animals and the
course of the stress reaction [54,88]. Concurrently, this class of compounds had an exceptional breadth
on the biological activity spectrum [38–52]. Such pleiotropic actions served as the basis for the search
for a single mechanism capable of influencing both the course of the inflammatory process and the
stress reaction.
According to the results of in vivo experiments, the immunomodulatory cardioprotective effects
of substituted 1,3,4-thiadiazines in MI, expressed in the reduction of MI size (the formation of only a
subepicardial infarction) and the prevention of its recurrence, were due to their action not only in the
ischemic tissues but, also, on the severity of the stress reaction [96,97].
The study cycle conducted in silico allowed revelation of the main targets regarding the action of
compounds within several 1,3,4-thiadiazines which included receptors and transporters of serotonergic,
adrenergic and dopaminergic systems. Additionally, the potentially high activity of chemical
compounds on the blockade of JAK3 was determined. Moreover, if the influence of the activity of the
compound upon the neurotransmitter systems on the course of the stress reaction is understandable, the
effect of the blockade of the kinase signal pathway PI3K-AKT requires further research. The possibility
of such influence has already been described: some anti-depression drugs that were used in anatomical
models of “sickness behavior” and in human depression clinical trials were shown to suppress the
clinical markers of inflammation, as well as SAPK/MAPK and/or JAK/STAT signaling in vitro [127].
Later, the experimental work of Jiang et al. (2017) also revealed that antidepressant-like effects of
magnesium isoglycyrrhizinate and fluoxetine might be mediated by the JAK/STAT/NF-κB signaling
pathway [128].
Thus, the described effects of substituted 1,3,4-thiadiazines convinced the authors of the need
to search for a new agents for limiting the peripheral inflammatory/ischemic damage through the
central mechanisms of stress reaction and modifying pro-inflammatory cytokine signaling pathways
in the brain.
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